This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan (AGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter 2020 results.
BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q1 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q1 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
by Zacks Equity Research
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports first-quarter results.
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.
Is a Beat in Store for Abeona (ABEO) This Earnings Season?
by Zacks Equity Research
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.
Factors Setting the Tone for Novartis' (NVS) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with the impact of the coronavirus pandemic on its outlook when Novartis (NVS) reports first-quarter 2020 results.
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports first-quarter results.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up
by Zacks Equity Research
Alexion (ALXN) gains as it announces plans to initiate a study to evaluate Ultomiris for the COVID-19 infection.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.
6 Valuable Price-to-Book Stocks to Buy as Recession Lurks
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.
Coronavirus Ravaging Your Portfolio? 4 Low P/CF Stocks to Buy
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
10 Stocks Leading the Rally in the S&P 500 ETF
by Sweta Killa
Signs of a slowdown in the number of hospitalizations and intensive-care admissions in New York and Europe has led to optimism over the reopening of the economy soon and improving activity in the near future.
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. QGEN: Which Stock Is the Better Value Option?
Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $89.93 in the latest trading session, marking a +0.16% move from the prior day.